All News

Xeljanz4.jpg

Is Methotrexate Necessary with Tofacitinib?

d RheumNow

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Read Article
meeting.audience.3.jpg

EULAR 2019- Day 4 Report

d Jack Cush, MD

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.



Below are the top “LB” presentations from EULAR this year:

Read Article
#EULAR2019 Come hear the latest on gout! Room N103 16:15-17:45 today. Risk:Exciting new genetics, occupational hazard, diet and inflammation. Treatment: New effectiveness measure, DECT to diagnose, flare prophylaxis, treat to target to prevent increased mortality @rheumnow #gout

Gout Study Group GoutGroup ( View Tweet)

#Gout and #genetics at #EULAR2019. New data on genes linked to sUA regulation and leading-edge genetics on conversion from #hyperuricemia to gout were shown in talks OP47 and OP48 @Rheumnow https://t.co/d6pikodu6K
Gout Study Group GoutGroup ( View Tweet)

A study examined whether EGCG suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty #inflammation. It was found that EGCG reduces inflammation in mouse foot tissue making it a promising treatment option for #gout https://t.co/X9O2mbJx6A https://t.co/wgUYz0BmeY

Links:

Gout Study Group GoutGroup ( View Tweet)
PARE poster tour II: @SjogrenpowerAna presenting poster “Patient Voice in Gout: A European Patient Survey to understand the needs of people living with #gout” #agony (37%) #frustation (32%) inconvenience (53%) & 10% of patients have retired because of gout #Time2Work #EULAR2019 https://t.co/qUQoYt3nKL
Victoria Romero romeropazosvic ( View Tweet)
Achilles’ tendon issues can be painful and disabling, and are something we all want to avoid. Dr Simon Otter presents imaging data at #EULAR2019 showing loss of Achilles’ tendon stiffness-ability to bear load-in the gout patients in his cohort. Abstract SAT0727 #gout @RheumNow https://t.co/yxhcpQsGBi
Gout Study Group GoutGroup ( View Tweet)
It’s been a fantastic meeting - this is me, signing off from #EULAR2019 in Madrid! @RheumNow https://t.co/iYAcClaFMR https://t.co/JQkXXNqdVN

Links:

David Liew drdavidliew ( View Tweet)
That’s a wrap! Thank you to all delegates, speakers, submitters and exhibitors for making #EULAR2019 unforgettable! https://t.co/RSa6DkCPt1
EULAR | The European League Against Rheumatism eular_org ( View Tweet)
And off we go. Thank you #EULAR2019. Thank you #Madrid. What a beautiful city. We enjoyed seeing our friends on this side of the planet for a change. We look forward to Frankfurt 2020. Adiós! https://t.co/vT8bURmkpJ
The Journal of Rheumatology jrheum ( View Tweet)
Further commentary in @RheumJnl from Peter Taylor - definitely a space to watch https://t.co/74St0w4DmS

Links:

David Liew drdavidliew ( View Tweet)

Pilot vagal nerve stimulation for RA: interesting with clinical and immunological response, but surgical complications and lack of imaging data as yet. Also 4x/day worse than daily: too often might breed resistance? Looking forward to seeing more #EULAR2019 LB0009 @RheumNow https://t.co/VZCl0RBlbq
David Liew drdavidliew ( View Tweet)
See you next year in Frankfurt or at ACR1 19 #EULAR2020 #ACR19 https://t.co/xVlWViuGgj

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 https://t.co/KvxoPhvyS6
Dr. John Cush RheumNow ( View Tweet)
Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acute phase reactants. 3. treated with Tocilizumab vs. placebo for 48 wks EARLY SSc; elevated acute phase reactants; anti-IL-6 inhibition--> PRESERVATION OF ILD https://t.co/63lwR1G0Cp
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
Going beyond scleroderma. 1. Tanezumab is effective for OA related pain and no new safety concerns. #EULAR2019 https://t.co/Uohex1uybS
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single dose. —there were more flares with low dose but less SI. — DAS 28 response was similar #EULAR2019

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Exercise program 30 min 12w (combination of generalised upper limb and specific hand exercises) helps to improve pain, function, dexterity, QOL over time more so than controlled group #eular2019 @RheumNow

Alberta Hoi tuna0sashimi ( View Tweet)

MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achieved LDA (CDAI <=10) n>200 each arm no difference between arms consistent with anecdotal evidence of how pt can withdraw MTX in real life. #eular2019 @RheumNow

Alberta Hoi tuna0sashimi ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×